Type 2 diabetes is a progressive chronic disease in which the body both becomes resistant to insulin and produces insufficient insulin resulting in elevated blood sugar levels. These elevated blood sugar levels can lead to serious complications including cardiovascular disease, peripheral vascular disease, neuropathies, and retinopathies. Diabetes kills more Americans each year than breast cancer and AIDS combined, and approximately 95% of all diabetic patients have type 2 diabetes.
Type 2 diabetes has been called a global epidemic, affecting over 350 million people worldwide and significantly diminishing their quality of life. Because of the significant complications associated with diabetes, people with the disease cost 2-3 times more to treat over their lifetimes than non-diabetics creating a financial challenge to health systems around the world. In the US alone, patients with diabetes cost the U.S. healthcare system $246 billion, a 41% increase over the prior five-year period.1 These costs are likely to increase further, driven by our aging population and the increasing number of patients developing type 2 diabetes.
The first step in controlling type 2 diabetes is lifestyle management, followed by oral antidiabetic drugs and ultimately insulin therapy. Significant investment in research and development of new oral antidiabetic drugs has generated a steady stream of new options, yet recent studies have shown that almost half of the people in the US and Europe with type 2 diabetes are unable to control their blood sugar levels with oral agents alone.2 Despite this fact, many patients are resistant to the idea of insulin therapy both due to the safety risks, side effects, and need for frequent injections.
For these reasons, physicians and their patients are seeking new non-pharmacologic options to fight type 2 diabetes that are less costly, less complicated and less dependent on patient compliance than today’s oral antidiabetic drugs. This is the opportunity that drives our company mission and focus: developing novel approaches for the treatment and management of type 2 diabetes, to help reduce the crushing personal and financial burden of the disease.
1American Diabetes Association. The Economic Costs of Diabetes in the U.S. in 2012; Diabetes Care. 2013.
2Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013; Lipska et al; Diabetes Care 2016 Sep; dc160985
The Metabolic Neuromodulation System is not currently approved in any region and is limited to investigational use only for the COMPLEMENT study. CAUTION: INVESTIGATIONAL DEVICE, LIMITED TO INVESTIGATIONAL USE.